Investigational drug · Phase 3
Fixed of Pertuzumab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
35
Any phase or sponsor naming "Fixed of Pertuzumab"
First trial start
2022
Jul 5, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Fixed of Pertuzumab", any sponsor or status.
- Phase 223
Conditions studied
As listed on its trial records.
- Early Breast Cancer
- Locally Advanced Breast Cancer
- Inflammatory Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Fixed of Pertuzumab" as an intervention, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02291289 · 1,044 participants · Start Apr 17, 2015 · Primary completion May 31, 2019
Drug: Cetuximab; FOLFOX induction regimen and 9 more · For: Colorectal Cancer
Sites: Buenos Aires, Argentina; La Rioja, Argentina; Viedma Rio Negro, Argentina · 154 sites in all
- A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05296798 · 922 participants (planned) · Start Jul 18, 2022 · Primary completion Jun 15, 2028
Drug: Phesgo; Giredestrant and 4 more · For: Locally Advanced or Metastatic Breast Cancer
Sites: Tucson, Arizona; Los Angeles, California; Jacksonville, Florida · 198 sites in all
- Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast CancerPivotal-lookingRecruiting
Henan Cancer HospitalGovernment (non-federal)
NCT07057427 · 812 participants (planned) · Start Jun 24, 2025 · Primary completion Jun 30, 2028
Drug: Nab paclitaxel; Docetaxel and Carboplatin and 1 more · For: Breast Cancer
Sites: Zhengzhou, China
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03493854 · 500 participants · Start Jun 14, 2018 · Primary completion Jul 4, 2019
Drug: Cyclophosphamide; Doxorubicin and 7 more · For: Early Breast Cancer
Sites: Rockville, Maryland; Farmington, New Mexico; Charlotte, North Carolina · 107 sites in all
- A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast CancerActive, not recruiting
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT04569747 · 393 participants · Start Jan 11, 2021 · Primary completion Mar 23, 2029
Drug: ADJUVANT ENDOCRINE THERAPY · For: HER2-positive Breast Cancer; Invasive Carcinoma of the Breast; Breast Cancer and 3 more
Sites: Stamford, Connecticut; Miami, Florida; Atlanta, Georgia · 32 sites in all
- Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast CancerActive, not recruiting
MedSIRAcademic, hospital or other
NCT04733118 · 393 participants · Start Aug 5, 2021 · Primary completion Mar 2027
Drug: Trastuzumab and Pertuzumab (FDC SC) and T-DM1 · For: Early Breast Cancer
Sites: Sofia, Bulgaria; Cologne, Germany; Duisburg, Germany · 41 sites in all
- Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.Pivotal-lookingActive, not recruiting
MedSIRAcademic, hospital or other
NCT03161353 · 377 participants · Start Jun 26, 2017 · Primary completion Nov 1, 2023
Drug: Perjeta; Herceptin and 4 more · For: Breast Cancer
Sites: Brussels, Belgium; Clermont-Ferrand, France; Nancy, France · 56 sites in all
- TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal CancerPivotal-lookingRecruiting
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Academic, hospital or other
NCT05188313 · 376 participants (planned) · Start Mar 9, 2022 · Primary completion Jul 2027
Drug: Trastuzumab; Pertuzumab and 2 more · For: Esophageal Cancer; Esophageal Adenocarcinoma
Sites: Amsterdam, Netherlands
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05415215 · 346 participants · Start Jul 5, 2022 · Primary completion Nov 20, 2024
Drug: Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC); Pertuzumab IV and 3 more · For: Early Breast Cancer; Locally Advanced Breast Cancer; Inflammatory Breast Cancer
Sites: Buenos Aires, Argentina; Ciudad Autonoma Buenos Aires, Argentina; Banja Luka, Bosnia and Herzegovina · 45 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Early Breast Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- LHRH AgonistPhase 36 trials
Roche (Genentech) · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer, Early Breast Cancer, Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.